KCM
PDLI

Kennedy Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Kennedy Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-315,620
Closed -$1.17M – 763
2019
Q1 		$1.17M Sell
315,620
-6,422,158
-95% -$21.7M 0.03% 602
2018
Q4 		$19.5M Sell
6,737,778
-345,080
-5% -$948K 0.49% 22
2018
Q3 		$18.6M Buy
7,082,858
+5,322,482
+302% +$13.1M 0.35% 55
2018
Q2 		$4.12M Buy
+1,760,376
New +$4.91M 0.08% 469

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Kennedy Capital Management's PDLI Position: Q2 2019 in Review

Kennedy Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2019, closing a stake of 315,620 shares — an estimated $1.17M sold.

Kennedy Capital Management first reported a position in PDLI in Q2 2018 and held it in 4 quarters. The position peaked at $19.5M in Q4 2018. 148 funds tracked by Wall St. Rank hold PDLI as of Q2 2019.

  • Kennedy Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2019 after selling out during the quarter.
  • Kennedy Capital Management sold 315,620 PDL BioPharma, Inc. shares in Q2 2019, an estimated $1.17M.
  • Kennedy Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2018 and held it in 4 quarters.
  • Kennedy Capital Management's PDL BioPharma, Inc. position peaked at $19.5M in Q4 2018.
  • 148 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2019.

Based on Kennedy Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.